Literature DB >> 22248276

Pretransplant serum ferritin level may be a predictive marker for outcomes in patients having undergone allogeneic hematopoietic stem cell transplantation.

S Sivgin1, S Baldane, L Kaynar, F Kurnaz, C Pala, A Ozturk, M Cetin, A Unal, B Eser.   

Abstract

Iron overload increases the risk of infections, veno-occlusive disease and hepatic dysfunction in post-transplant period. Our objective was to investigate the association of pre-transplant ferritin levels with complications and survival after allogeneic hematopoietic stem cell transplantation (alloHSCT).We retrospectively analysed 84 patients' data who had undergone allogeneic HSCT into two groups: patients with a serum ferritin level ≥ 1000 ng/ml, and patients with <1000 ng/ml at the time of HSCT.Cox-regression analysis showed that pre-transplant serum ferritin levels were significantly higher in patients who had at least one infectious event compared with those who had no any infectious event in the post-transplant 100 days (p<0.023). Overall survival (OS) and disease-free survival (DFS) rates were significantly higher in patients with a time-to-tx interval 12 months (p=0.002 and p=0.008 respectively). A higher risk of death was observed in high-ferritin group (hazard ratio=2.27, CI:1.01-5.09, p=0.023 for OS and hazard ratio=2.49, CI:1.12-5.53 p=0.039 for DFS). No significant effect on OS and DFS among groups was observed for variables conditioning regimen, gender and diagnosis. Acute GVHD was more common in patients with a ferritin level ≥ 1000 ng /mL, but this was not statistically significant (p>0.05). There was no statistical significance in both groups (ferritin ≥ 1000 ng /mL and ferritin <1000 ng/mL) for relapse rates (p>0.05). Platelet and neutrophil engaftment day was not found statistically significant compared with both groups (p=0.273 and p=0.882, respectively). Pre-transplant ferritin levels may predict poor outcomes in patients who had undergone allogeneic hematopoietic stem cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22248276     DOI: 10.4149/neo_2012_024

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  11 in total

1.  Refinement of the Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation.

Authors:  Yasuhiko Shibasaki; Tatsuya Suwabe; Takayuki Katagiri; Tomoyuki Tanaka; Takashi Ushiki; Kyoko Fuse; Naoko Sato; Toshio Yano; Takashi Kuroha; Shigeo Hashimoto; Miwako Narita; Tatsuo Furukawa; Hirohito Sone; Masayoshi Masuko
Journal:  Int J Hematol       Date:  2018-05-09       Impact factor: 2.490

2.  Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation.

Authors:  Jennifer E Vaughn; Barry E Storer; Philippe Armand; Roberto Raimondi; Christopher Gibson; Alessandro Rambaldi; Fabio Ciceri; Rosi Oneto; Benedetto Bruno; Paul J Martin; Brenda M Sandmaier; Rainer Storb; Mohamed L Sorror
Journal:  Biol Blood Marrow Transplant       Date:  2015-04-07       Impact factor: 5.742

3.  Prevalence and risk factors of iron overload after hematopoietic stem cell transplantation for childhood acute leukemia: a LEA study.

Authors:  A Sirvent; P Auquier; C Oudin; Y Bertrand; S Bohrer; P Chastagner; M Poirée; J Kanold; S Thouvenin; Y Perel; D Plantaz; M-D Tabone; K Yakouben; V Gandemer; P Lutz; N Sirvent; C Vercasson; J Berbis; H Chambost; G Leverger; A Baruchel; G Michel
Journal:  Bone Marrow Transplant       Date:  2016-09-05       Impact factor: 5.483

4.  Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation.

Authors:  Carlos Vallejo; Montserrat Batlle; Lourdes Vázquez; Carlos Solano; Antonia Sampol; Rafael Duarte; Dolores Hernández; Javier López; Montserrat Rovira; Santiago Jiménez; David Valcárcel; Vicente Belloch; Mónica Jiménez; Isidro Jarque
Journal:  Haematologica       Date:  2014-07-04       Impact factor: 9.941

5.  Cyclophosphamide-based in vivo T-cell depletion for HLA-haploidentical transplantation in Fanconi anemia.

Authors:  M S Thakar; C Bonfim; B M Sandmaier; P O'Donnell; L Ribeiro; T Gooley; H J Deeg; M E Flowers; R Pasquini; R Storb; A E Woolfrey; H P Kiem
Journal:  Pediatr Hematol Oncol       Date:  2012-07-27       Impact factor: 1.969

6.  Impact of pretransplant red cell transfusion on outcome after allogeneic stem cell transplantation in adult patients with severe aplastic anemia.

Authors:  S-E Lee; S-A Yahng; B-S Cho; K-S Eom; Y-J Kim; H-J Kim; C-K Min; S Lee; S-G Cho; D-W Kim; W-S Min; J W Lee
Journal:  Bone Marrow Transplant       Date:  2016-05-23       Impact factor: 5.483

Review 7.  Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy.

Authors:  Olga Blau; Igor Wolfgang Blau
Journal:  Stem Cells Cloning       Date:  2014-12-04

Review 8.  Effect of pre-transplantation serum ferritin on outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation: A meta-analysis.

Authors:  Zhengwei Yan; Xianying Chen; Huiping Wang; Yaling Chen; Lihong Chen; Peilin Wu; Wei Wang
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

9.  Neck infection after allogenic hematopoietic progenitors transplantation.

Authors:  J Mensa; C Dueñas Gutiérrez; C Cardozo; L Rodríguez Fernández; M Kestler; P Muñoz; E Bouza
Journal:  Rev Esp Quimioter       Date:  2020-02-14       Impact factor: 1.553

10.  A novel differential predict model based on matrix-assisted laser ionization time-of-flight mass spectrometry and serum ferritin for acute graft-versus-host disease.

Authors:  Chun-Yan Zhang; Shu-Hong Wang; Wen-Rong Huang; Guang-Hong Guo; Zhu-Hong Zhang; Wen-Jun Mou; Li Yu; Ya-Ping Tian
Journal:  Biomed Res Int       Date:  2013-10-01       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.